Science & Enterprise subscription

Follow us on Twitter

  • A clinical trial began enrolling participants to collect real world evidence on a digital therapy designed to relie… https://t.co/AMuUt4C0oh
    about 5 hours ago
  • New post on Science and Enterprise: Trial Underway Assessing Insomnia Therapy App https://t.co/qmdNHoo382 #Science #Business
    about 5 hours ago
  • This week's report shows a marked increase in activity on therapies, while the number of vaccines in development an… https://t.co/Z7P2ivWaxJ
    about 13 hours ago
  • New post on Science and Enterprise: Covid-19 Vaccines, Therapies – 13 July 2020 https://t.co/epfuGPmjdy #Science #Business
    about 13 hours ago
  • This is nuts. Manufacturing, distribution, and public health infrastructure here are more important than who made t… https://t.co/AOHVdFBlrX
    about 1 day ago

Please share Science & Enterprise

Scripps Institute, Sigma-Aldrich to Partner on Reagents

Beakers (Research.gov)

(Research.gov)

Scripps Research Institute in La Jolla, California is collaborating with Sigma-Aldrich Corp. in St. Louis to speed the availability of new chemical reagents for drug discovery to the scientific community. The deal calls for payments to Scripps from Sigma-Aldrich, a chemical and laboratory services company, although the size of the payments is not disclosed.

Under the agreement, Sigma-Aldrich will receive an exclusive license to commercialize new reagents developed in six labs at Scripps: Phil Baran, Carlos Barbas, Benjamin CravattPhillip DawsonBarry Sharpless, and Jin-Quan Yu. The research conducted in the labs covers various aspects of chemistry, biochemistry, and molecular biology.

Sigma-Aldrich will provide payments to Scripps for the research conducted in the labs that results in the discovery of new reagent compounds. The company will also assign a product number to each of the new reagents, and make them available to the research community on the same day as their publication in scientific journals.

Scripps and Sigma-Aldrich are already partnering on commercializing a collection of 10 zinc-based salts developed in the lab of Phil Baran. Scripps says one of the salts, a difluoromethylation reagent, is being used in large quantities by pharmaceutical companies for optimizing lead compounds.

In the past year, Scripps also established research collaborations with Janssen Pharmaceuticals and Bristol-Myers Squibb. This new deal is the first multi-lab partnership for Scripps with Sigma-Aldrich, or any other chemical supplier.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.